Novo Nordisk’s semaglutide ... Association for the Study of Diabetes (EASD) 2016 and also published in the New England Journal of Medicine. The US Food and Drug Administration requires ...

LONDON, March 12 (Reuters) - The Novo Nordisk ... diabetes products, represented a potential conflict of interest. They also noted links between some of the people involved in the project and the ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...